Novacyt announces update on strategic review of non-core assets NOVAprep® and clinical laboratory enter formal sales process Novacyt to enhance focus on core profitable diagnostic products business
Visit PageCategory: Products
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2018/12/NOVACYT_CP_Droits-de-vote_2018-Dec.pdf
Visit PageCompletion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market
Novacyt q16 order in China Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular
Visit Page